Taking stock of the drug industry, from the lab to the medicine chestDecember 19, 2024Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Justin Sullivan/Getty Images STAT+ | Gilead plans to halt free access to an HIV drug, worrying patient advocates This is "an unnecessary complication" for people who can't easily afford $20 or $30 a month for generics," said Jeremiah Johnson of PrEP4All. By Ed Silverman STAT+ | Health plan formularies lowered barriers to fair access to some drugs, analysis finds The mixed findings suggest that patients still face significant barriers to access because of policy choices made by payers. By Ed Silverman STAT+ | FDA confirms shortage of weight loss drug tirzepatide is over, gives compounders a grace period The action could set a precedent for how the agency handles Novo Nordisk's semaglutide. By Elaine Chen, Katie Palmer, Ed Silverman, and Lizzy Lawrence PATRICK T. FALLON/AFP via Getty Images STAT+ | Feds accuse CVS of filling 'thousands' of illicit opioid prescriptions The suit alleged CVS "ignored substantial evidence from multiple sources... indicating its stores were dispensing unlawful prescriptions." By Ed Silverman STAT+ | Vertex touts pain drug results, but medicine does not outperform placebo in sciatica study The pain drug, called suzetrigine, did not lead to a bigger drop in patients' pain scores than a placebo did. By Matthew Herper and Jonathan Wosen More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments